Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Winquist

Showing results (221-230 of 234) with videos related to

Pageof 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2021
Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update ConsortiumSilke Gillessen, Nicolas Sauvé, Laurence Collette, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 16, 2024
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III StudyRobert J Motzer, Camillo Porta, Masatoshi Eto, et al.
The New England Journal of Medicine|December 12, 2012
Abiraterone in metastatic prostate cancer without previous chemotherapyCharles J Ryan, Matthew R Smith, Johann S de Bono, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2024
Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update ConsortiumEmanuel Bührer, David D'Haese, Gedske Daugaard, et al.
The New England Journal of Medicine|February 22, 2021
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell CarcinomaRobert Motzer, Boris Alekseev, Sun-Young Rha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2021
Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update ConsortiumJörg Beyer, Laurence Collette, Nicolas Sauvé, et al.
JAMA|December 11, 2008
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)Scott M Lippman, Eric A Klein, Phyllis J Goodman, et al.
European Urology|August 15, 2024
First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter StudyTalal El Zarif, Karl Semaan, Wanling Xie, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2025
Radiation vs. trans-oral surgery for treatment de-escalation in HPV-related oropharyngeal cancers: Primary analysis of the ORATOR2 randomized trialDavid A Palma, Eitan Prisman, Eric Berthelet, et al.
Nature Communications|February 27, 2026
Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancerDavid C Müller, Andrew J Murtha, Jack V W Bacon, et al.
Pageof 24

Showing results (221-230 of 234) with videos related to

Sort By:
Pageof 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2021
Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update ConsortiumSilke Gillessen, Nicolas Sauvé, Laurence Collette, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 16, 2024
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III StudyRobert J Motzer, Camillo Porta, Masatoshi Eto, et al.
The New England Journal of Medicine|December 12, 2012
Abiraterone in metastatic prostate cancer without previous chemotherapyCharles J Ryan, Matthew R Smith, Johann S de Bono, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2024
Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update ConsortiumEmanuel Bührer, David D'Haese, Gedske Daugaard, et al.
The New England Journal of Medicine|February 22, 2021
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell CarcinomaRobert Motzer, Boris Alekseev, Sun-Young Rha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2021
Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update ConsortiumJörg Beyer, Laurence Collette, Nicolas Sauvé, et al.
JAMA|December 11, 2008
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)Scott M Lippman, Eric A Klein, Phyllis J Goodman, et al.
European Urology|August 15, 2024
First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter StudyTalal El Zarif, Karl Semaan, Wanling Xie, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2025
Radiation vs. trans-oral surgery for treatment de-escalation in HPV-related oropharyngeal cancers: Primary analysis of the ORATOR2 randomized trialDavid A Palma, Eitan Prisman, Eric Berthelet, et al.
Nature Communications|February 27, 2026
Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancerDavid C Müller, Andrew J Murtha, Jack V W Bacon, et al.
Pageof 24